INDOCO · NSE
Not in active coverage. Cited reporting has mentioned Indoco Remedies, the record of those mentions is below. Your interest is logged; coverage expands by demand.
Indoco Remedies' Goa plant (Plant I) successfully passed a UKMHRA cGMP inspection from September 7 to September 9, 2026, with no critical or major observations.
Indoco Remedies' manufacturing facility at Plant I in Goa successfully completed an inspection by the UK Medicines and Healthcare products Regulatory Agency (MHRA) from September 7, 2026, to September 9, 2026, with no critical or major observations.
The UK-MHRA current Good Manufacturing Practices (cGMP) inspection of Indoco Remedies' solid dosages manufacturing facility in Goa concluded with no critical or major observations.
The U.S. Food and Drug Administration (USFDA) inspected Indoco Remedies' manufacturing facility at Plant II (Sterile) located at Goa from August 27, 2026, to September 4, 2026, and issued seven observations in Form 483.
This page lists where cited reporting has mentioned Indoco Remedies. It is not the full dossier: developments here are single mentions, not corroborated records. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.